Cart is empty Glioblastoma (GBM) is the most aggressive and lethal form of brain cancer, with a median survival of only 15 months despite intensive treatment. Current therapies—including surgery, radiation, and chemotherapy—offer limited long-term benefit, and immune-based treatments have so far shown minimal success. The complexity of the tumor’s microenvironment and its ability to suppress immune responses contribute to the poor prognosis.
Leave A Comment